Clinical trial · Interventional
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
A Phase II Trial to Evaluate the Use of G-CSF-Mobilized Peripheral Blood Progenitor Cells as Hematopoietic Rescue in Patients With Acute Leukemia Undergoing Allografting From an Unrelated Donor
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as treatment for acute leukemia. PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 55 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * One of the following diagnoses: * Primary acute leukemia beyond first remission * High-risk acute myelogenous leukemia * Acute lymphoblastic leukemia in first remission * Must have HLA-matched donor identical for HLA-A, -B, and DRB1 alleles * No HLA-matched identical sibling or haploidentical relative incompatible for 0 or 1 HLA-A, -B, or -DRB1 loci on the non-shared haplotype * No leukoencephalopathy PATIENT CHARACTERISTICS: Age: * 55 and under Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * SGOT no greater than 2 times normal * Hepatitis B surface antigen negative * No prior hepatitis C Renal: * No impaired renal function * Creatinine less than 2 times normal Cardiovascular: * No symptomatic cardiac disease Pulmonary: * No active pulmonary disease * DLCO at least 60% predicted Other: * HIV negative * No disease or other malignancy that severely limits life expectancy * No severe or life-threatening infection within the past 2 weeks * No history of septate fungal infection or disseminated candidiasis PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior bone marrow or peripheral blood stem cell transplantation Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy greater than 3,000 cGy to whole brain * No prior radiotherapy of 1,500 cGy to chest or abdomen * At least 6 months since prior involved-field radiotherapy to chest or abdomen Surgery: * Not specified
References
Publications (0)
Data not yet available